Compared to Thursday’s closing price, shares of Thyrocare Technologies fell 66.7% in early trading on Friday, reaching an intraday low of Rs 492; Understand why
Thyrocare Technologies’ shares started trading ex-bonus after the company’s 2:1 bonus issue, and it fell 66.7% in early trading on Friday to an intraday low of Rs 492 from Thursday’s closing price of Rs 1,473.90.
Even while the steep decline seemed dramatic, it was only a mechanical adjustment related to the shares becoming ex-bonus and does not reflect a decline in investor confidence or the company’s fundamentals.
For each existing share owned, the business is issuing two fully paid-up equity shares with a face value of Rs 10 under the bonus issue, thereby tripling the total number of outstanding shares. The board accepted the action, shareholders gave their approval, and the stock exchanges were notified.
Friday, November 28, 2025 was set as the record date for identifying qualified stockholders. The shares became ex-bonus on the same day in accordance with stock exchange regulations, thus the bonus shares will only be awarded to investors who held the stock at the end of trading on November 28.
Monday, December 1 has been designated as the deemed date of allotment. The bonus shares are anticipated to be tradable on Tuesday, December 2. The bonus shares will be equal to current equity shares in every way, including dividend and voting rights, according to the company’s clarification.
The bonus issue’s main goals are to increase liquidity and promote greater retail involvement. This is Thyrocare Technologies’ first bonus issue, according to Trendlyne statistics.
Thyrocare is a major player in the Indian healthcare diagnostics market, providing hospitals, labs, and patients all throughout the country with a variety of reasonably priced diagnostic services.
